Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
暂无分享,去创建一个
Elizabeth Fisher | Jeffrey A Cohen | Jeffrey A. Cohen | Robert J Fox | R. Rudick | E. Fisher | R. Fox | J. Tkach | Richard A Rudick | Jar-Chi Lee | Jean Tkach | Jar‐chi Lee | Jeffrey A. Cohen
[1] J L Ostuni,et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.
[2] F Barkhof,et al. Optimizing the association between disability and biological markers in MS , 2001, Neurology.
[3] J Winter,et al. Steroids and Apparent Cerebral Atrophy on Computed Tomography Scans , 1978, Journal of computer assisted tomography.
[4] Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis. , 1999, Neurology.
[5] M. Oudega,et al. Long‐term effects of methylprednisolone following transection of adult rat spinal cord , 1999, The European journal of neuroscience.
[6] R I Grossman,et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. , 1992, Radiology.
[7] E. Hall. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury , 1993, Cellular and Molecular Neurobiology.
[8] J K Udupa,et al. Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.
[9] B. Lewis,et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b , 2002, Neurology.
[10] Elizabeth Fisher,et al. Knowledge-based 3D segmentation of the brain in MR images for quantitative multiple sclerosis lesion tracking , 1997, Medical Imaging.
[11] C H Polman,et al. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone , 2002, Multiple sclerosis.
[12] T. Harkany,et al. Action of Glucocorticoids on Survival of Nerve Cells: Promoting Neurodegeneration or Neuroprotection? 1 , 2001, Journal of neuroendocrinology.
[13] R. Rudick,et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.
[14] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[15] G. Barker,et al. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.
[16] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[17] Jayaram K. Udupa,et al. Comparison of T 2 Lesion Volume and Magnetization Transfer Ratio Histogram Analysis and of Atrophy and Measures of Lesion Burden in Patients with Multiple Sclerosis , 1998 .
[18] Neil Gordon,et al. Apparent Cerebral Atrophy in Patients on Treatment with Steroids , 1980, Developmental medicine and child neurology.
[19] G J Barker,et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.
[20] J H Simon,et al. Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.
[21] M. Horsfield,et al. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads , 1998, Journal of the Neurological Sciences.
[22] M Filippi,et al. Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms , 1999, Journal of the Neurological Sciences.